Fundraising Fox
Euphrates Vascular
St. Louis, US · Founded 2018 · Delaware corporation · 6 known investors
Find your way into Euphrates Vascular
Sign up to see every warm intro you have to Euphrates Vascular
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Euphrates Vascular team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Euphrates Vascular develops the Pulse NanoMED System, a nanoscale interventional medical device that uses magnetically guided iron-oxide nanoparticles to reach and disrupt distal vascular occlusions beyond the reach of wires and catheters. The technology targets complex vascular occlusions, including stroke, for interventional and vascular treatment.
Founders & leadership
Board
Investors · 6
How we know: Anthro Ventures's portfolio page · Not right? Tell us
How we know: Missouri Technology Corporation's portfolio page · Not right? Tell us
How we know: View Ventures's portfolio page · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$9.7M disclosed across 2 rounds · 2018–2020
▶$9.1MraisedOct 2023 · 33 investors · BiotechnologyRule 506(b)
- Cathy MatthesExecutive Officer
- Martin Omid AkhavanExecutive Officer, Director
- Sean MorrisDirector
- Offering amount
- $9.1M
- Amount sold
- $9.1M
- Minimum investment
- $5K
- Sales commissions
- $120.1K
- Placement agents
- CIM Securities LLC
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$590KraisedSep 2018 · 4 investors · BiotechnologyRule 506(b)
- Troy LongExecutive Officer
- Sean MorrisExecutive Officer, Director
- Jeffrey BlairDirector
- Tim BlairExecutive Officer
- Eric MoessingerDirector
- Robert MitchellDirector
- Thomas HillmanDirector
- Offering amount
- $4M
- Amount sold
- $590K
- Minimum investment
- $25K
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
Companies working in the same space as Euphrates Vascular.
Frequently asked questions
- What does Euphrates Vascular do?
- Euphrates Vascular develops the Pulse NanoMED System, a nanoscale interventional medical device that uses magnetically guided iron-oxide nanoparticles to reach and disrupt distal vascular occlusions beyond the reach of wires and catheters. The technology targets complex vascular occlusions, including stroke, for interventional and vascular treatment.
- Who are Euphrates Vascular's investors?
- Euphrates Vascular's investors include Anthro Ventures, Missouri Technology Corporation, OSF Ventures, View Ventures, +ND Capital, Cultivation Capital.
- How much funding has Euphrates Vascular raised?
- Euphrates Vascular has disclosed $9.7M raised across 2 rounds.
- Where is Euphrates Vascular headquartered?
- Euphrates Vascular is headquartered in St. Louis, US.